A researcher from Yale University is conducting a short, anonymous survey to learn more about how patients with CIDP have responded to Efgartigimod (also known as Vyvgart hytrulo). Your feedback will help us better understand its effects on symptoms, side effects, quality of life, and the overall treatment experience. This information will be invaluable in helping physicians and researchers improve care for others with CIDP.
This survey is not sponsored by any commercial entity. This is an investigator-initiated study to better understand the real-world therapeutic usage in CIDP. It will take less than 5 minutes of your valuable time and is completely anonymous and voluntary. The data will be stored electronically under the Qualtrics server for 2 years. While there is no compensation for participating, your input will contribute meaningfully to research that aims to improve care for others facing similar challenges.
For more information or to participate in this study, contact: neuromuscular_research@yale.edu
Spotlight
